At what enterprise value was GLOBAL D acquired in 2024?

During the acquisition of GLOBAL D by NAXICAP PARTNERS in 2024, the transaction's Enterprise Value is estimated to be in the range of 100M - 350M EUR.

What was the EV/EBITDA of GLOBAL D when it was acquired by NAXICAP PARTNERS?

The estimated EV/EBITDA multiple for GLOBAL D is in the range of 15x - 25x.

When was GLOBAL D acquired by NAXICAP PARTNERS?

GLOBAL D was acquired by NAXICAP PARTNERS in 2024.

What was the revenue of GLOBAL D at the time of the deal?

The revenue of GLOBAL D at the time of the deal is estimated to be in the range of 25M - 50M EUR.

What was the EBITDA of GLOBAL D during the acquisition?

GLOBAL D's EBITDA is estimated to be in the range of 5M - 25M EUR.

How is the data for the GLOBAL D acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the GLOBAL D deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.accuracy.com/global-d-sextrait-de-sa-maison-mere-cfnews/

← DATABASE

Home Database Healthcare & PharmaGLOBAL D

11/2024

GLOBAL D acquired by NAXICAP PARTNERS

FRANCE Life Sciences / Medical Devices / Implants & Prosthetics EV 100M - 350M EUR

Context

Naxicap Partners has acquired a majority stake (over 60%) in Global D, marking the company’s first independent LBO following its carve-out from the Menix Group. The remaining capital is held by a dozen managers led by the executive team. The transaction follows a competitive auction process and includes a financing package provided by Capza (unitranche and PIK debt) alongside a capex line from Banque Palatine. This strategic "independence" move follows the parent group's divestment of other assets to industrial giants. The rationale for this new cycle is to support the firm’s internationalization and active buy-and-build strategy, targeting niche acquisitions with revenues between 5 million and 20 million euros to complement its existing technology and geographic reach.

GLOBAL D, which reported an EBITDA margin of in 2024, is valued in this transaction at an EV/EBITDA multiple of , representing a to the average currently observed in the Healthcare & Pharma sector (14.5x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Founded in 2012 and based in Lyon, Global D is a leading French manufacturer of medical devices specializing in dental implantology and maxillofacial surgery. The company’s business model focuses on high-precision engineering and clinical support for over 15,000 clients, primarily private implantologists, dentists, and specialized surgical units in hospitals and clinics. Its product portfolio covers the entire range of dental reconstruction and facial bone repair. With a strong domestic leadership (70% of sales), the firm also operates subsidiaries in Poland and Italy and distributes its specialized medical devices in 30 countries globally. Its value proposition is built on technical innovation and deep expertise in the niche segment of bone integration and dental aesthetics.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2024

2023

Similar deals in Life Sciences

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
12/2024	GOLDMAN SACHS	Synthon International	NETHERLANDS	Generics / Labs
12/2024	NEXTSTAGE / IK PARTNERS	EUROBIO SCIENTIFIC	FRANCE	Diagnostic Equipment
10/2024	CLAYTON, DUBILIER & RICE (CD&R)	OPELLA	FRANCE	Generics / Labs
10/2024	KKR / KREFELD	ANJAC BEAUTY & HEALTH	FRANCE	CDMO
10/2024	BANSK GROUP	PETIQ	UNITED STATES	Animal Health
09/2024	AGILENT TECHNOLOGIES	BIOVECTRA	CANADA	CDMO
08/2024	RECURSION PHARMACEUTICALS	EXSCIENTIA	UNITED KINGDOM	R&D Biotech
08/2024	NORDSON CORPORATION	ATRION CORPORATION	UNITED STATES	Diagnostic Equipment
07/2024	ASTORG	NEXPRING HEALTH EX HAMILTON THORNE	UNITED STATES	Medical Devices
07/2024	ROCHE	LUMIRADX	UNITED KINGDOM	Diagnostic Equipment

REFERENCES

Valuation range: EV 100M - 350M EUR

Revenue range: 25M - 50M EUR

EBITDA range: 5M - 25M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of GLOBAL D by NAXICAP PARTNERS are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Acquirer: naxicap partners